PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30984874-12	2018	Galantamine and memantine via the alpha7nACh and NMDA receptors can counteract the effects of kynurenic acid and enhance MMN and BDNF.	Memantine	16-25	brain derived neurotrophic factor	Homo sapiens	129-133	
19521778-0	2009	An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons.	Memantine	69-78	brain derived neurotrophic factor	Homo sapiens	18-22	
19521778-7	2009	Furthermore, the ELISA studies showed increased cellular and released BDNF protein level after combined treatment with memantine and staurosporine.	Memantine	119-128	brain derived neurotrophic factor	Homo sapiens	70-74	
33174139-0	2021	Memantine, NMDA Receptor Antagonist, Attenuates ox-LDL-Induced Inflammation and Oxidative Stress via Activation of BDNF/TrkB Signaling Pathway in HUVECs.	Memantine	0-9	brain derived neurotrophic factor	Homo sapiens	115-119	
30344474-0	2018	Corrigendum: Prenatal Deltamethrin Exposure-Induced Cognitive Impairment in Offspring Is Ameliorated by Memantine Through NMDAR/BDNF Signaling in Hippocampus.	Memantine	104-113	brain derived neurotrophic factor	Homo sapiens	128-132	
29656414-3	2018	We investigated whether add-on memantine to regular valproic acid treatment ameliorated clinical symptoms, reduced alcohol use, and cytokine levels, and increased plasma brain-derived neurotrophic factor (BDNF) in BD-II patients with comorbid alcohol dependence.	Memantine	31-40	brain derived neurotrophic factor	Homo sapiens	170-203	
29656414-3	2018	We investigated whether add-on memantine to regular valproic acid treatment ameliorated clinical symptoms, reduced alcohol use, and cytokine levels, and increased plasma brain-derived neurotrophic factor (BDNF) in BD-II patients with comorbid alcohol dependence.	Memantine	31-40	brain derived neurotrophic factor	Homo sapiens	205-209	
29656414-9	2018	CONCLUSIONS: BD-II comorbid with alcohol dependence might benefit from add-on memantine treatment, which significantly reduced clinical severity, alcohol use, and plasma cytokine levels, and increased BDNF levels.	Memantine	78-87	brain derived neurotrophic factor	Homo sapiens	201-205	
29695962-8	2018	Moreover, NMDAR inhibition by memantine also prevented Abeta-driven deleterious impact of BDNF loss of function on structural (spine density) and functional outcomes (synaptic potentiation).	Memantine	30-39	brain derived neurotrophic factor	Homo sapiens	90-94	
26660109-6	2016	Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes.	Memantine	15-24	brain derived neurotrophic factor	Homo sapiens	86-90	
24103632-7	2014	To adjust within-subject dependence over repeated assessments, multiple linear regression with generalized estimating equation methods was used to analyze the effects of the BDNF Val66Met polymorphism on the clinical performance of memantine.	Memantine	232-241	brain derived neurotrophic factor	Homo sapiens	174-178	
24103632-10	2014	We conclude that the BDNF Val66Met polymorphism influenced responses to add-on memantine by decreasing depressive symptoms in patients with BP-II.	Memantine	79-88	brain derived neurotrophic factor	Homo sapiens	21-25